JPWO2019173291A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019173291A5
JPWO2019173291A5 JP2020546997A JP2020546997A JPWO2019173291A5 JP WO2019173291 A5 JPWO2019173291 A5 JP WO2019173291A5 JP 2020546997 A JP2020546997 A JP 2020546997A JP 2020546997 A JP2020546997 A JP 2020546997A JP WO2019173291 A5 JPWO2019173291 A5 JP WO2019173291A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
polypeptide sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020546997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516057A (ja
JP7334177B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020688 external-priority patent/WO2019173291A1/en
Publication of JP2021516057A publication Critical patent/JP2021516057A/ja
Publication of JPWO2019173291A5 publication Critical patent/JPWO2019173291A5/ja
Priority to JP2023132024A priority Critical patent/JP7636483B2/ja
Application granted granted Critical
Publication of JP7334177B2 publication Critical patent/JP7334177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020546997A 2018-03-09 2019-03-05 抗cd73抗体及びその使用 Active JP7334177B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023132024A JP7636483B2 (ja) 2018-03-09 2023-08-14 抗cd73抗体及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862640955P 2018-03-09 2018-03-09
US62/640,955 2018-03-09
US201862721044P 2018-08-22 2018-08-22
US62/721,044 2018-08-22
US201862786598P 2018-12-31 2018-12-31
US62/786,598 2018-12-31
PCT/US2019/020688 WO2019173291A1 (en) 2018-03-09 2019-03-05 Anti-cd73 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023132024A Division JP7636483B2 (ja) 2018-03-09 2023-08-14 抗cd73抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021516057A JP2021516057A (ja) 2021-07-01
JPWO2019173291A5 true JPWO2019173291A5 (enExample) 2022-03-10
JP7334177B2 JP7334177B2 (ja) 2023-08-28

Family

ID=67846304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546997A Active JP7334177B2 (ja) 2018-03-09 2019-03-05 抗cd73抗体及びその使用
JP2023132024A Active JP7636483B2 (ja) 2018-03-09 2023-08-14 抗cd73抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023132024A Active JP7636483B2 (ja) 2018-03-09 2023-08-14 抗cd73抗体及びその使用

Country Status (13)

Country Link
US (1) US11299550B2 (enExample)
EP (1) EP3762030A4 (enExample)
JP (2) JP7334177B2 (enExample)
KR (2) KR102804816B1 (enExample)
CN (2) CN118955714A (enExample)
AU (1) AU2019231172B2 (enExample)
BR (1) BR112020016049A2 (enExample)
CA (1) CA3090008A1 (enExample)
IL (1) IL276950B1 (enExample)
MX (1) MX2020009366A (enExample)
SG (1) SG11202007199XA (enExample)
WO (1) WO2019173291A1 (enExample)
ZA (1) ZA202004827B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019067425A1 (en) 2017-09-26 2019-04-04 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES
PE20251291A1 (es) 2018-02-27 2025-05-14 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション A2a/a2b阻害剤としての縮合ピリミジン誘導体
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
WO2020072996A1 (en) 2018-10-05 2020-04-09 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MX2022003465A (es) * 2019-09-23 2022-06-16 Univ Pennsylvania Anticuerpo monoclonal contra proteína de activación de fibroblasto canino de reacción cruzada con proteína de activación de fibroblasto (fap) de ratón y humana.
CN114746438A (zh) 2019-09-23 2022-07-12 宾夕法尼亚大学董事会 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
CN115003385A (zh) * 2019-11-15 2022-09-02 建新公司 双互补位cd73抗体
EP4061420A1 (en) * 2019-11-20 2022-09-28 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
MX2022007513A (es) * 2019-12-17 2022-07-05 Phanes Therapeutics Inc Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
CA3166536A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021138467A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
WO2021202807A1 (en) * 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
US12523662B2 (en) 2020-04-02 2026-01-13 Seattle Children's Hospital Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
US20230159655A1 (en) * 2020-04-22 2023-05-25 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
US20230151111A1 (en) * 2020-04-22 2023-05-18 Akeso Biopharma, Inc Anti-cd73-anti-pd-1 bispecific antibody and use thereof
WO2021222746A2 (en) * 2020-04-30 2021-11-04 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
CA3191745A1 (en) * 2020-08-17 2022-02-24 Akeso Biopharma, Inc. Anti-cd73 antibody and use thereof
CA3196299A1 (en) * 2020-10-23 2022-04-28 Baiyong Li Anti-cd73 antibody and use thereof
CN117126281A (zh) * 2020-11-09 2023-11-28 江苏中新医药有限公司 抗cd73单克隆抗体及其在制备肿瘤药物中的应用
TWI900705B (zh) * 2020-12-11 2025-10-11 大陸商上海華奧泰生物藥業股份有限公司 Cd73的抗原結合蛋白及其應用
JP2024502005A (ja) 2020-12-29 2024-01-17 インサイト・コーポレイション A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法
CN113061177B (zh) * 2020-12-31 2022-07-01 浙江大学 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法
EP4299589A4 (en) * 2021-02-24 2025-06-11 Novoprotein Scientififc Inc. HUMAN ANTI-CD73 ANTIBODY AND ITS USE
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
IL310866A (en) * 2021-08-19 2024-04-01 Adicet Therapeutics Inc Methods for the detection of membrane-bound glypican-3
CN116265486A (zh) * 2021-12-17 2023-06-20 三生国健药业(上海)股份有限公司 结合人cd73的抗体、其制备方法和用途
US12187806B2 (en) * 2022-03-04 2025-01-07 Development Center For Biotechnology Anti-CD73 antibodies and use thereof
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN116063467B (zh) * 2022-08-24 2025-10-14 浙江大学医学院附属第一医院 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用
WO2024243189A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Antigen binding proteins targeting pd-1
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN117567632B (zh) * 2023-11-27 2025-10-24 福州迈新生物技术开发有限公司 抗cd73蛋白单克隆抗体及其制备方法和应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
FR3011240A1 (fr) 2013-10-01 2015-04-03 Centre Nat Rech Scient Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques
US10654884B2 (en) 2014-04-25 2020-05-19 Boehringer Ingelheim International Gmbh Purine derivatives as CD73 inhibitors for the treatment of cancer
KR102536786B1 (ko) 2014-10-10 2023-05-26 이나뜨 파르마 에스.에이. Cd73 차단
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
MY191423A (en) * 2014-11-10 2022-06-27 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
EA035766B1 (ru) * 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения
BR112017010094A2 (pt) 2014-11-21 2018-02-06 Bristol-Myers Squibb Company anticorpos compreendendo regiões constantes de cadeias pesadas modificadas
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
EP3387442A4 (en) * 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES
WO2017118613A1 (en) 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
CN109476740A (zh) 2016-03-04 2019-03-15 百时美施贵宝公司 利用抗cd73抗体的联合治疗
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies

Similar Documents

Publication Publication Date Title
JPWO2019173291A5 (enExample)
US20220220218A1 (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP7209464B2 (ja) ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
IL310938A (en) Anti-CCR8 antibodies and their uses
CN115960232A (zh) 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
JP2021500916A5 (enExample)
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
JP2021512652A5 (enExample)
JP2023518225A (ja) ムチン17に対する抗体及びその使用
CN113840836A (zh) 抗结缔组织生长因子抗体及其应用
JPWO2019177854A5 (enExample)
JPWO2023020621A5 (enExample)
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
KR20230119693A (ko) 면역글로불린 경쇄 항체 및 이의 용도
JP2023550780A (ja) 二重特異性抗体およびその用途
WO2025146161A1 (en) Antibody, antigen-binding fragment and medical use thereof
WO2023227115A1 (en) A method of treating solid tumor
CN120040594B (zh) 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用
CN121362251A (zh) 抗il-5抗体、其药物组合物及用途
NZ766968B2 (en) Anti-cd73 antibodies and uses thereof